Association of finerenone with prognosis and safety in diabetic kidney disease patients: an undated meta-analysis based on four RCTs.

ABSTRACT:

Background

Although current guidelines have recommended finerenone as a first-line agent for patients with diabetic kidney disease (DKD), it is unclear what effect finerenone has on all-cause and cardiovascular mortality. This study aimed to assess the impact of finerenone on the prognosis and safety of patients with DKD.

Methods

A systematic search was performed in PubMed, Embase, Scopus, and Web of Science. We included randomized controlled trials involving patients diagnosed with DKD that had finerenone versus placebo. The number of deaths, including any cause and cardiovascular causes, hyperkalemia, and adverse events, were collected for the finerenone and placebo groups. Data were summarized as risk ratio (RR) with 95% confidence interval (95% CI).

Results

Four t

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC12267240 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature